Abcodia is a clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer. The Company’s first product is the ROCA® Test for the early detection of ovarian cancer. It is also expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer.
Our products are based on expertise in measuring and modelling dynamic changes over time of serum-based biomarkers before cancer is clinically diagnosed and it maintains exclusive commercial access to a biobank of prospectively collected samples donated from over 200,000 individuals over a 10-year period.
We hold strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovative Capital plc, Scottish Equity Partners and UCL Business Plc. Headquartered in Cambridge, U.K., the Company maintains a U.S. corporate presence in Boston.